This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Vivian Xie
25 Aug 2022

Thermo Fisher Scientific expands viral vector manufacturing capabilities with Plainville facility

Thermo Fisher Scientific’s new Plainville, MA viral vector manufacturing facility has opened, expanding the company's cell and gene therapy capabilities with advancing bioproduction and analytical instrumentation technologies.

Scientific services provider Thermo Fisher Scientific has opened the doors to its new viral vector manufacturing facility in Plainville, MA, expanding its cell and gene therapy capabilities with a new state-of-the-art facility with the addition of a 300,000 square foot site adding approximately 300 jobs in support of the development, testing, and manufacturing of viral vectors – critical components in gene therapies.

The Plainville facility will greatly expand Thermo Fisher’s viral vector capacity to six sites across the United States and Europe, featuring a sustainable design, flexible laboratory and production suites, warehousing, and office space. It will also advance the company’s bioproduction and analytical instrumentation technologies. As part of an investment strategy hoping to provide fully integrated capabilities to connect the cell and gene therapy value and supply chain, the facility will also provide translational sciences labs for early-stage development, viral vector services, and cell therapy manufacturing with integrated packaging and distribution services, amongst others. More than 130 viral vector products have been produced by Thermo Fisher for the treatment of cancer, blood disorders, and other genetic diseases. 

Chairman, President, and CEO of Thermo Fisher Scientific Marc N. Casper stated: "Plainville is an impressive addition to our pharma services network as we continue to invest and innovate cell and gene therapy services, products, and workflows... We are enabling our customers to speed their scientific discoveries in cell and gene therapy while also supporting their manufacturing needs, whether they are early in the development process or ready to transition to clinical or commercial scale.” 

The new Patheon Quick to Clinic viral vector manufacturing platform is an additional all-inclusive manufacturing platform that uses IND-ready processes for lentivirus and adeno-associated virus manufacturing for rapid process development, further accelerating the discovery-to-clinic pipeline. 

Congressman Jack Auchincloss concluded: “Massachusetts is the world capital of life sciences, with a footprint of biomedical innovation that extends well beyond Cambridge and Boston... Thermo Fisher Scientific’s new, state-of-the-art viral vector manufacturing facility in Plainville is a clear statement from a world-class company that the Commonwealth is not just the leader in R&D, but also in biomanufacturing.” 

Source: Thermo Fisher Scientific Expands Viral Vector Manufacturing Capabilities | Newsroom | Thermo Fisher Scientific 

Vivian Xie
Editor - Custom Content

Related News